Enzo Biochem (NYSE:ENZ) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a note issued to investors on Wednesday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Trading Down 1.9 %

Shares of NYSE ENZ opened at $0.73 on Wednesday. Enzo Biochem has a 12-month low of $0.68 and a 12-month high of $1.50. The firm’s 50-day simple moving average is $1.04 and its 200 day simple moving average is $1.09.

Enzo Biochem (NYSE:ENZ) last announced its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.

Institutional Trading of Enzo Biochem

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BBR Partners LLC bought a new position in shares of Enzo Biochem in the 3rd quarter worth $112,000. Renaissance Technologies LLC boosted its holdings in Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after buying an additional 64,417 shares during the last quarter. XTX Topco Ltd increased its stake in shares of Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 13,735 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after acquiring an additional 11,742 shares during the last quarter. 36.90% of the stock is owned by institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.